The Lancet HIV
| 1. | [Comment] Closing the equity gap in the treatment of HIV-2 infection | Sarah Rowland-Jones, Ester Gea-Mallorquí | |
| 2. | [Articles] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial | Serge P Eholie, Didier K Ekouevi, Corine Chazallon, Charlotte Charpentier, Eugène Messou, Zelica Diallo, Jacques Zoungrana, Albert Minga, Ndeye Fatou Ngom Gueye, Denise Hawerlander, Fassery Dembele, Géraldine Colin, Boris Tchounga, Sophie Karcher, Jérome Le Carrou, Annick Tchabert-Guié, Thomas-d'Aquin Toni, Abdoul-Salam Ouédraogo, Guillaume Bado, Coumba Toure Kane, Moussa Seydi, Armel Poda, Ephrem Mensah, Illah Diallo, Youssouf Joseph Drabo, Xavier Anglaret, Françoise Brun-Vezinet, FIT-2 study group | |
| 3. | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial | Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie Klopfer, Isaias Gendrano, Karen Eves, Todd A Correll, Michelle C Fox, Jason Kim | |
| 4. | [Comment] Is this the end of the road for daily islatravir 0·75 mg? | Jennifer Hoy, James McMahon | |
| 5. | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial | Anthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Debbie P Hagins, Roger Paredes, Jacques Reynes, Jürgen K Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, Rebeca M Plank, Todd Correll, Michelle C Fox | |
| 6. | [Correspondence] Context-specific estimates of vertical transmission | Souleymane Tassembedo, Isidore Tiandiogo Traore, Abdoul-Salam Ouedraogo, Nicolas Meda, Philippe Van de Perre, Nicolas Nagot, Fati Kirakoya-Samadoulougou | |
| 7. | [Viewpoint] Two-drug regimens for the treatment of HIV in Africa | Ivan Mambule, Claire Norcross, Loice Achieng Ombajo, Simiso Sokhela, Eva Agnes Laker Odongpiny, Noela Owarwo, David S Lawrence, Eugene Ruzagira, Fiona V Cresswell | |
| 8. | [Corrections] Correction to Lancet HIV 2024; 11: e86–95 | | |
| 9. | [Corrections] Correction to Lancet HIV 2024; 11: e64–65 | | |
| 10. | [Feature] Tajikistan's tentative steps to tackling HIV | Ed Holt | |
| 11. | [Culture] An eventful conference | Fio Trethewey | |
| 12. | [Culture] No money, no treatment—living on the edge | Talha Burki | |
| 13. | [Culture] Closeted life of a Hollywood giant | Talha Burki | |
| 14. | [Corrections] Correction to Lancet HIV 2023; 10: e663–73 | | |
| 15. | [Corrections] Correction to Lancet HIV 2023; 10: e713–22 | |
更新于 24 分钟前
近期历史最近 100 条记录
| 2024-05-11 | [Comment] Closing the equity gap in the treatment of HIV-2 infection | Sarah Rowland-Jones, Ester Gea-Mallorquí | |
| 2024-05-11 | [Articles] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial | Serge P Eholie, Didier K Ekouevi, Corine Chazallon, Charlotte Charpentier, Eugène Messou, Zelica Diallo, Jacques Zoungrana, Albert Minga, Ndeye Fatou Ngom Gueye, Denise Hawerlander, Fassery Dembele, Géraldine Colin, Boris Tchounga, Sophie Karcher, Jérome | |
| 2024-05-09 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial | Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie Klopfer, Isaias Gendrano, Karen Eves, Todd A Correll, Mic | |
| 2024-05-09 | [Comment] Is this the end of the road for daily islatravir 0·75 mg? | Jennifer Hoy, James McMahon | |
| 2024-05-09 | [Articles] Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-b | Anthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Debbie P Hagins, Roger Paredes, Jacques Reynes, Jürgen K Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, Rebeca M Plank, Todd Correll, Mich | |
| 2024-05-01 | [Correspondence] Context-specific estimates of vertical transmission | Souleymane Tassembedo, Isidore Tiandiogo Traore, Abdoul-Salam Ouedraogo, Nicolas Meda, Philippe Van de Perre, Nicolas Nagot, Fati Kirakoya-Samadoulougou | |
| 2024-04-30 | [Viewpoint] Two-drug regimens for the treatment of HIV in Africa | Ivan Mambule, Claire Norcross, Loice Achieng Ombajo, Simiso Sokhela, Eva Agnes Laker Odongpiny, Noela Owarwo, David S Lawrence, Eugene Ruzagira, Fiona V Cresswell | |
| 2024-04-13 | [Articles] Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study | Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth HellstrÖm, Afaaf Liberty, Eric J McGrath, Meenu Kaur, Rory Leisegang, Jason T Hindman, Vinicius A Vieir | |
| 2024-04-13 | [Articles] Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, | Dathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella d'Arminio Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric Fontas, Irene Abela, | |
| 2024-04-13 | [Comment] Expanding options of child-friendly, single-tablet regimens for young children with HIV | Tim R Cressey, Anna Turkova | |
| 2024-04-13 | [Comment] More pressure on integrase strand-transfer inhibitors? | Anton L Pozniak, W D Francois Venter | |
| 2024-04-09 | [Review] Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians | Andrés Esteban-Cantos, Rocío Montejano, Adriana Pinto-Martínez, Javier Rodríguez-Centeno, Federico Pulido, José R Arribas | |
| 2024-04-06 | [Corrections] Correction to Lancet HIV 2024; 11: e86–95 | | |
| 2024-04-05 | [Articles] Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial | Sunil S Solomon, Allison M McFall, Aylur K Srikrishnan, Vinita Verma, Santhanam Anand, Rifa T Khan, Bhawani Singh Kushwaha, Canjeevaram Vasudevan, Shanmugam Saravanan, Nandagopal Paneerselvam, Muniratnam Suresh Kumar, Chinmoyee Das, David D Celentano, Shr | |
| 2024-04-05 | [Comment] Enhancing HIV care with incentives: one size does not fit all | Sandra I McCoy, Amon Sabasaba | |
| 2024-04-04 | [Comment] Intersectional climate justice, health equity, and HIV | Sarah M Wilson, Griffin Woolley, Chris Hawn, Kate Hoffman, Akhenaton-Andrew D Jones, Cliburn Chan, Sarah V Mudrak, M Umar Qureshi, Ashley Ward, Elizabeth T Knippler, N Lance Okeke, Amy Corneli, Georgia D Tomaras, R Keith Reeves | |
| 2024-03-29 | [Corrections] Correction to Lancet HIV 2024; 11: e64–65 | | |
| 2024-03-28 | [Feature] Tajikistan's tentative steps to tackling HIV | Ed Holt | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
